Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?

Basit Öğe Kaydı
dc.contributor.authorKaralezli, Aylin
dc.contributor.authorKucukerdonmez, Cem
dc.contributor.authorAkova, Yonca A.
dc.contributor.authorKoktekir, Bengu Ekinci
dc.date.accessioned2020-03-26T18:50:08Z
dc.date.available2020-03-26T18:50:08Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAIM: To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal -conjunctival autograft transplantation (LCAT). METHODS: eighty -eight eyes of 88 patients with primary pterygium were included. Pterygia were graded preoperatively from type 1 to type 3 (type 1 atrophic, type 3 inflamed) according to the inflammatory status. The eyes were preoperatively randomized to receive topical steroid and antibiotic treatment (group 1, 46 eyes) and additional topical bevacizumab (5 mg/mL; group 2, 42 eyes) in the postoperative period. All eyes underwent pterygium excision and LCAT. Medications were tapered and discontinued at one month. Postoperative complications and recurrence rates were recorded. RESULTS: The mean follow -up duration was 29.3 +/- 4.2mo (24-52mo) and 28.5 +/- 3.4 (24-48mo) in group 1 and 2, respectively (P>0.05). There were no statistically significant differences regarding the age or gender between groups (P>0.05). Also, the difference between groups with respect to pterygium type was not significant. During the follow -up period, recurrence developed in 2 eyes (4.3%) in group 1, whereas in one eye (2.4%) in group 2. No statistically significant difference between groups was found in recurrence rates (P>0.05). No re-operation for recurrence was necessary during the follow-up period in both groups. CONCLUSION: Topical bevacizumab seems to have no additonal effect on pterygium recurrence after LCAT.en_US
dc.identifier.doi10.3980/j.issn.2222-3959.2014.03.23en_US
dc.identifier.endpage516en_US
dc.identifier.issn2222-3959en_US
dc.identifier.issn2227-4898en_US
dc.identifier.issue3en_US
dc.identifier.pmid24967201en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage512en_US
dc.identifier.urihttps://dx.doi.org/10.3980/j.issn.2222-3959.2014.03.23
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30755
dc.identifier.volume7en_US
dc.identifier.wosWOS:000337658400023en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIJO PRESSen_US
dc.relation.ispartofINTERNATIONAL JOURNAL OF OPHTHALMOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectlimbal-conjuctival autograften_US
dc.subjecttopical bevacizumaben_US
dc.subjectpterygiumen_US
dc.subjectrecurrenceen_US
dc.subjecttopical bevacizumaben_US
dc.titleDoes topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu